Rgenta Therapeutics
Focus: Rgenta Therapeutics is an RNA-targeting biotech focused on gene therapy medicines, headquartered in Woburn, MA. The company operates at an early stage with a single Phase 1 program in clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Rgenta Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Rgenta Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
RGT-61159
Adenoid Cystic CarcinomaClinical Trials (1)
NCT06462183Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Phase 1Help build intelligence for Rgenta Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.